Post by : Raman

Pfizer has reached an agreement with the Trump administration to lower the cost of prescription medicines for Medicaid patients and offer discounts directly to consumers through a new government-backed platform called TrumpRx, U.S. President Donald Trump announced on Tuesday.

The announcement was made at the White House alongside Pfizer CEO Albert Bourla, just hours before a possible government shutdown over disputes on health care and spending. Trump said the deal marks the first step in a broader plan to pressure pharmaceutical companies to reduce prices or face new tariffs.

What the Pfizer Deal Includes

Under the agreement, Pfizer will provide “most-favored-nation pricing” to Medicaid. This means the company will match the lowest drug prices it offers in other developed countries and apply that pricing to new medicines as well.

In addition, Pfizer will participate in the TrumpRx website, a new government platform that allows people to purchase drugs directly from manufacturers. Pfizer said many of its medicines will be offered at an average discount of 50% on the site.

Pfizer produces some of the world’s most widely used medicines, including the COVID-19 vaccine Comirnaty, Paxlovid (antiviral treatment), Eliquis (blood thinner), Prevnar pneumonia vaccines, and several cancer drugs.

Impact on Patients and Medicaid

The new pricing system is expected to begin in 2026, according to senior officials. Medicaid patients, who already pay small co-payments, could benefit through reduced state healthcare costs. Uninsured Americans, who often struggle to afford medicines, may also see some relief through the TrumpRx platform.

However, experts caution that even a 50% discount may not make some treatments affordable. For example, cancer therapies and specialty medicines could still cost patients hundreds of dollars each month.

Stacie Dusetzina, a professor at Vanderbilt University Medical Center, said the details of the deal remain unclear. While some patients may benefit, she noted that “this is not a complete solution for lowering drug prices” in the U.S.

Pfizer’s U.S. Investment Commitment

As part of the deal, Pfizer also pledged to invest $70 billion in domestic research, development, and manufacturing projects over the next few years. The move aligns with the Trump administration’s push to bring more drug production back to the United States.

Trump said the agreement shows how his administration is “turning the tide” against unfair pricing practices. He credited the threat of tariffs as a key bargaining tool, saying it gave the government “a strong negotiating position.”

Political Debate Over Drug Pricing

The Pfizer deal comes amid intense political debate in Washington. While Trump highlights the deal as a win for consumers, critics argue the changes will not significantly lower prices for most Americans. Democrats, meanwhile, are fighting to reverse Medicaid cuts included in a recent law signed by Trump, pushing for healthcare protections to be included in upcoming budget negotiations.

Trump also sent letters earlier this summer to executives at 17 major pharmaceutical companies, demanding they adopt similar pricing rules. He claimed that high U.S. drug prices effectively subsidize lower costs in other countries, and pledged that more agreements with other drugmakers would be announced soon.

The deal’s success will depend on how prices are implemented and whether other pharmaceutical companies follow Pfizer’s lead. While TrumpRx may provide discounts for some consumers, experts warn that structural reforms in the U.S. drug pricing system are still needed to make medicines affordable for all.

#world news #Global News #Donald Trump